Adhere to listed medical necessity criteria

Adhere to listed medical necessity criteria. Document indication and clinical rationale when using LMWHs or thrombin inhibitors, including but not limited to: major orthopedic or abdominal-pelvic cancer surgery (note extended prophylaxis durations where applicable), pregnancy-associated thrombotic conditions or antiphospholipid syndrome, cancer-associated VTE (initial and continued therapy), and heparin-induced thrombocytopenia (HIT).

• Major orthopedic surgery (hip/knee)
• Major abdominal-pelvic surgery for cancer (consider extended 4-week prophylaxis)
• Pregnancy thrombotic conditions and antiphospholipid syndrome
• Cancer-associated VTE (initial 5–10 days and continued ≥6 months; consider indefinite anticoagulation for selected patients with active/metastatic cancer)
• Heparin-induced thrombocytopenia (HIT) — use alternative agents such as argatroban

Report appropriate J-codes

Report appropriate J‑codes for injectable anticoagulants per payer billing guidance. Include diagnosis linkage and documentation supporting medical necessity on the claim.

• J1645
• J1650
• J1652
• J1655
• J0883
• J0884
• J0891
• J0892
• J0898
• J0899

Reassess anticoagulation duration for cancer patients

Assess ongoing anticoagulation beyond 6 months in members with cancer-associated VTE. Document active cancer status (e.g., metastatic disease, receiving chemotherapy), bleeding risk assessment, and rationale if indefinite or extended anticoagulation is continued.

Check drug–drug interactions for DOAC use

Review and document potential drug–drug interactions prior to using direct oral anticoagulants (DOACs) and when transitioning between agents. Note interactions with strong CYP3A4 and P‑glycoprotein inhibitors/inducers and concomitant chemotherapy agents.

Perioperative prophylaxis for major cancer surgery

For perioperative prophylaxis in major cancer surgery, document procedure type, estimated VTE risk, and plan for duration of prophylaxis. For high‑risk cancer surgeries, consider extended prophylaxis up to 4 weeks and document indication for extended duration.

Evidence context for use of LMWH/DTI

State the evidence context when using LMWHs or direct thrombin inhibitors: LMWHs are supported for prevention and treatment of VTE in multiple settings (orthopedic surgery, medical inpatients with severe immobility, cancer‑associated VTE) and may offer practical advantages over UFH; some uses remain experimental or investigational — document how the requested use aligns with established indications.

Argatroban indications and dosing notes

Argatroban is indicated for treatment of thrombosis in patients with HIT and for anticoagulation in percutaneous coronary intervention in patients with HIT. Document indication and monitor hepatic function; dosing is typically weight‑based with adjustments for hepatic impairment and continuous infusion in inpatient settings — include dosing rationale in the record.

Desirudin dosing and monitoring

Desirudin dosing and monitoring: document indication (e.g., VTE prophylaxis in hip replacement per labeling), dose administered, timing relative to surgery (first dose typically 15 minutes before surgery for some regimens or postoperative per prescribing information), and any required laboratory monitoring or renal function considerations.

Risk-factor documentation for multiple myeloma patients on thalidomide/lenalidomide

Document VTE risk factors for members with multiple myeloma who are receiving thalidomide or lenalidomide. Include patient‑specific risk factors (e.g., prior VTE, obesity, immobilization, central venous catheter, concurrent high‑dose corticosteroids, comorbidities) and the prophylactic strategy chosen.

Select prophylaxis duration by surgical context

Select and document the duration of prophylaxis based on surgical context and individual risk (e.g., up to 35 days for hip surgery, up to 2 weeks for knee surgery, up to 4 weeks for high‑risk cancer abdominal‑pelvic surgery). Note rationale when deviating from typical durations.